docetaxel anhydrous has been researched along with osimertinib in 5 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (osimertinib) | Trials (osimertinib) | Recent Studies (post-2010) (osimertinib) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 1,315 | 134 | 1,282 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | osimertinib (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 1 | |
| Lysine-specific histone demethylase 1A | Homo sapiens (human) | 3.98 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.1858 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0274 | |
| Insulin receptor | Homo sapiens (human) | 0.912 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 3.26 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.0268 | |
| von Hippel-Lindau disease tumor suppressor | Homo sapiens (human) | 0.002 | |
| Histone deacetylase 4 | Homo sapiens (human) | 1 | |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | 0.0395 | |
| Epidermal growth factor receptor | Mus musculus (house mouse) | 0.081 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.57 | |
| Histone deacetylase 1 | Homo sapiens (human) | 1 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.033 | |
| Histone deacetylase 7 | Homo sapiens (human) | 1 | |
| Histone deacetylase 2 | Homo sapiens (human) | 1 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 1 | |
| Histone deacetylase 11 | Homo sapiens (human) | 1 | |
| Histone deacetylase 8 | Homo sapiens (human) | 1 | |
| Histone deacetylase 6 | Homo sapiens (human) | 1 | |
| Histone deacetylase 9 | Homo sapiens (human) | 1 | |
| ALK tyrosine kinase receptor | Homo sapiens (human) | 0.177 | |
| Histone deacetylase 5 | Homo sapiens (human) | 1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geng, C; Ji, Y; Lan, K; Liu, S; Nie, K; Wang, S; Xu, X; Zhang, C; Zhang, L; Zhang, Z; Zhuang, X | 1 |
| Iwami, E; Kuroda, A; Matsuzaki, T; Nakajima, T; Sasahara, K; Terashima, T | 1 |
| Guan, H; Liu, G; Sheng, Y; Shi, L; Xie, F | 1 |
| Li, H; Rui, M | 1 |
| Hayashi, H; Kasahara-Kiritani, M; Nishio, M; Takahashi, M; Tsuchiya, H | 1 |
1 trial(s) available for docetaxel anhydrous and osimertinib
| Article | Year |
|---|---|
Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer.
Topics: Acrylamides; Adult; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Proportional Hazards Models | 2018 |
4 other study(ies) available for docetaxel anhydrous and osimertinib
| Article | Year |
|---|---|
A case report of metastatic lung adenocarcinoma with long-term survival for over 11 years.
Topics: Acrylamides; Aged; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Piperazines; Protein Kinase Inhibitors | 2019 |
Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic | 2019 |
Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in Third-line Treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China.
Topics: Acrylamides; Aniline Compounds; Bevacizumab; Carcinoma, Non-Small-Cell Lung; China; Cost-Benefit Analysis; Docetaxel; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quality-Adjusted Life Years | 2020 |
Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Platinum; Protein Kinase Inhibitors; Treatment Outcome | 2023 |